Seelos Therapeutics Inc (SEEL)

[RVL]

Just out on PR news wire
RVL
Apricus Biosciences Inc. Research Report
On June 10, 2013, Apricus Biosciences Inc. (Apricus Bio) announced that its marketing application for Vitaros, indicated for the treatment of patients with erectile dysfunction (ED), has been approved through the European Decentralized Procedure (DCP). Commenting on the approval, Richard Pascoe, Chief Executive Officer of Apricus Bio, said, "With its rapid onset of action and unique topical delivery, we believe that Vitaros will capture a significant share of the approximately $1 billion PDE-5 inhibitor market in Europe once it is launched by our commercial partners." Under the DCP, the Company filed its application for marketing approval designating Netherlands as the Reference Member State (RMS) on behalf of nine other European Concerned Member States (CMS) participating in the procedure. The CMS include France, Germany, Italy, UK, Ireland, Spain, Sweden, Belgium, and Luxembourg. Apricus Bio will continue to work independently as well as with its commercialization partners, Sandoz, Takeda, and Bracco for the next step of obtaining national phase approvals in order to make Vitaros ready to launch in each of the included territories across Europe. The Full Research Report on Apricus Biosciences Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/2aca_APRI]


Read more: http://www.nasdaq.com/article/new-research-grants-product-launches-and-positive-clinical-study-results---research-report-on-boston-scientific-cooper-arena-pharmaceuticals-apricus-biosciences-and-newlink-genetics-20130613-00230#ixzz2W6FRJTby